share_log

Panbela Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(0%),Lind Global Partners II LLC(0%), etc.

Panbela Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-Lind Global Fund II LP(0%),Lind Global Partners II LLC(0%)等

SEC announcement ·  02/14 09:16
牛牛AI助理已提取核心訊息
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons, regarding their holdings in Panbela Therapeutics, Inc. The amendment indicates that the Reporting Persons no longer beneficially own more than five percent of Panbela Therapeutics' common stock, as they report owning 0 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares previously held by Lind Global Fund II LP. The filing was certified by Jeff Easton on February 13, 2024, and includes a joint filing agreement among the Reporting Persons.
On December 31, 2023, a Schedule 13G amendment was filed with the SEC by Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, collectively referred to as the Reporting Persons, regarding their holdings in Panbela Therapeutics, Inc. The amendment indicates that the Reporting Persons no longer beneficially own more than five percent of Panbela Therapeutics' common stock, as they report owning 0 shares. Jeff Easton, as the managing member of Lind Global Partners II LLC and the general partner of Lind Global Fund II LP, is deemed to have sole voting and dispositive power over the shares previously held by Lind Global Fund II LP. The filing was certified by Jeff Easton on February 13, 2024, and includes a joint filing agreement among the Reporting Persons.
2023年12月31日，Lind Global Fund II LLC、Lind Global Partners II LLC和Jeff Easton（統稱爲申報人）就其持有的Panbela Therapeutics, Inc.向美國證券交易委員會提交了附表13G修正案。該修正案表明，申報人不再實益擁有Panbela Therapeutics超過5％的普通股，因爲他們報告擁有0股。傑夫·伊斯頓作爲Lind Global Partners II LLC的管理成員和Lind Global Fund II LP的普通合夥人，被視爲對Lind Global Fund II LP先前持有的股票擁有唯一的投票權和處置權。該文件於2024年2月13日由傑夫·伊斯頓認證，其中包括申報人之間的聯合申報協議。
2023年12月31日，Lind Global Fund II LLC、Lind Global Partners II LLC和Jeff Easton（統稱爲申報人）就其持有的Panbela Therapeutics, Inc.向美國證券交易委員會提交了附表13G修正案。該修正案表明，申報人不再實益擁有Panbela Therapeutics超過5％的普通股，因爲他們報告擁有0股。傑夫·伊斯頓作爲Lind Global Partners II LLC的管理成員和Lind Global Fund II LP的普通合夥人，被視爲對Lind Global Fund II LP先前持有的股票擁有唯一的投票權和處置權。該文件於2024年2月13日由傑夫·伊斯頓認證，其中包括申報人之間的聯合申報協議。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。